Targets › ABCAM
1 program from 1 company in 1 trial: 1 Phase 2; Immunology; next expected readout Nov 2026.
Open in Phaseline: the race on ABCAM, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| KeyBioscience | KBP-336 Dual Amylin and Calcitonin Receptor agonist | CALCR, ABCAM | Phase 2 | Osteoarthritis in the Knee | Nov 2026 |
Osteoarthritis in the Knee (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.